Since 1982, systemic Roaccutan has been used to treat acne that is resistant to traditional therapy. The treatment produces certain side effects and a potential for teratogenesis. The result has been worldwide reports of a number of malformed and abnormal infants. In the present questionnaire presented to 94 Norwegian women of child-bearing potential, no pregnancy occurred during the treatment period. Before start of treatment, all patients agreed to have an abortion if conception occurred during treatment. The article discusses the type of contraception, the quality of information and the effect of treatment upon the acne condition. The study confirms the importance of Roaccutan in the treatment of cystic acne, and shows that the Norwegian prescription routine for Roaccutan is adequate.